CN103919765B - 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 - Google Patents
高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 Download PDFInfo
- Publication number
- CN103919765B CN103919765B CN201410169644.3A CN201410169644A CN103919765B CN 103919765 B CN103919765 B CN 103919765B CN 201410169644 A CN201410169644 A CN 201410169644A CN 103919765 B CN103919765 B CN 103919765B
- Authority
- CN
- China
- Prior art keywords
- dinatin
- catechol
- levodopa
- pharmaceutical composition
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 title claims abstract description 88
- IHFBPDAQLQOCBX-UHFFFAOYSA-N hispidulin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C=C1 IHFBPDAQLQOCBX-UHFFFAOYSA-N 0.000 title claims abstract description 62
- OETSANFHEJPBHW-UHFFFAOYSA-N hispidulin Natural products COc1cc2c(cc1O)oc(cc2=O)-c1ccc(O)cc1 OETSANFHEJPBHW-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 239000012747 synergistic agent Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 42
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960004502 levodopa Drugs 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000000890 drug combination Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000002503 metabolic effect Effects 0.000 abstract description 6
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 abstract description 5
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 17
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 17
- -1 catechin Natural products 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 8
- 229960004603 tolcapone Drugs 0.000 description 8
- 229940126159 COMT enzyme inhibitor Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000001035 methylating effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- GMRNMZUSKYJXGJ-UHFFFAOYSA-N Fraxetin Natural products C1=CC(=O)C(=O)C2=C1C=C(OC)C(O)=C2O GMRNMZUSKYJXGJ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 241000244317 Tillandsia usneoides Species 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- HAVWRBANWNTOJX-UHFFFAOYSA-N fraxetin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2O HAVWRBANWNTOJX-UHFFFAOYSA-N 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- UWARRXZVZDFPQU-UHFFFAOYSA-N Sorbifolin Natural products C=1C(=O)C=2C(O)=C(O)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 UWARRXZVZDFPQU-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410169644.3A CN103919765B (zh) | 2014-04-24 | 2014-04-24 | 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410169644.3A CN103919765B (zh) | 2014-04-24 | 2014-04-24 | 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103919765A CN103919765A (zh) | 2014-07-16 |
CN103919765B true CN103919765B (zh) | 2016-06-15 |
Family
ID=51138314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410169644.3A Expired - Fee Related CN103919765B (zh) | 2014-04-24 | 2014-04-24 | 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103919765B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180034030A (ko) * | 2016-09-27 | 2018-04-04 | (주)아모레퍼시픽 | 소장 상피세포에서의 카테킨 흡수 증진제 |
CN108524490B (zh) * | 2018-05-23 | 2022-11-29 | 昆明理工大学 | 一种预防和治疗脑中风的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643465A (zh) * | 2009-08-14 | 2010-02-10 | 东华大学 | 一种comt抑制剂5,6,7,3',4'-五甲氧基异黄酮的制备方法 |
CN102755312A (zh) * | 2012-07-16 | 2012-10-31 | 中国科学院大连化学物理研究所 | 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用 |
CN103211832A (zh) * | 2013-04-24 | 2013-07-24 | 无锡艾德美特生物科技有限公司 | 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途 |
-
2014
- 2014-04-24 CN CN201410169644.3A patent/CN103919765B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643465A (zh) * | 2009-08-14 | 2010-02-10 | 东华大学 | 一种comt抑制剂5,6,7,3',4'-五甲氧基异黄酮的制备方法 |
CN102755312A (zh) * | 2012-07-16 | 2012-10-31 | 中国科学院大连化学物理研究所 | 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用 |
CN103211832A (zh) * | 2013-04-24 | 2013-07-24 | 无锡艾德美特生物科技有限公司 | 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103919765A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103211832A (zh) | 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途 | |
Guo et al. | Evaluation of antiviral effect and toxicity of total flavonoids extracted from Robinia pseudoacacia cv. idaho | |
CN102526022A (zh) | 表没食子儿茶素没食子酸酯在制备抗肿瘤药物中的应用 | |
CN103989677A (zh) | 去亚甲基小檗碱在制备降血糖药物中的应用 | |
CN103919765B (zh) | 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 | |
CN109453123A (zh) | 一种康普瑞汀类衍生物冻干粉针及其制备方法 | |
CN102755312A (zh) | 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用 | |
CN103536922B (zh) | 酰基辅酶a:胆固醇酰基转移酶‑2抑制剂在抑制肝癌生长中的应用 | |
CN104940181A (zh) | β-羟丁酸或其药学上可接受的盐的用途 | |
CN102138938B (zh) | 一种用于制备改善高尿酸血症的产品的组合物 | |
CN104116730A (zh) | 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用 | |
CN101756955A (zh) | 知母宁复合物及其制备方法和应用 | |
CN100546578C (zh) | 一种抗癌药物组合物及其在制备抗癌药物中的应用 | |
CN100502867C (zh) | 青藤碱用于抗肿瘤药物的制备 | |
CN102283984A (zh) | 一种瓜蒌薤白白酒汤整合型新剂型制备技术 | |
CN110101802A (zh) | 一种治疗高血压的药物组合物 | |
CN102526081A (zh) | 一种抑制肿瘤细胞增殖的药物组合物 | |
CN101249138B (zh) | 一种含五味子乙醇提取物的抗艾滋病药物组合物 | |
CN102526033B (zh) | 由表没食子儿茶素没食子酸酯与丝裂霉素c制成的抑制肿瘤细胞增殖的组合物 | |
US20140275138A1 (en) | Method and products for treating diabetes | |
CN100396295C (zh) | 一种治疗病毒性肝炎的药物 | |
CN103536921A (zh) | 胆固醇代谢物在抑制肝癌生长中的应用 | |
CN103193768B (zh) | 治疗肝病的水飞蓟宾二偏琥珀酸酯异构体 | |
CN102552265A (zh) | 包含表没食子儿茶素没食子酸酯与喜树碱的药物组合物 | |
CN100525776C (zh) | 全乙酰葛根素在制备治疗缺血性脑血管病新药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190410 Address after: 214092 No. 88-B23, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Patentee after: WUXI ERYUN TECHNOLOGY Co.,Ltd. Address before: 214092 No. 88-A34, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Patentee before: WUXI AIDE MEITE BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: 110000 No. 400-21 Zhihui Second Street, Hunnan District, Shenyang City, Liaoning Province Patentee after: SHENYANG BEICHUANG MEDICAL LABORATORY Co.,Ltd. Address before: 214092, Wuxi, Jiangsu Province, Binhu District, Mashan Mei Lu West No. 88 -B23 Patentee before: WUXI ERYUN TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160615 |
|
CF01 | Termination of patent right due to non-payment of annual fee |